Sign in
CompletedNo phase

Effects of Metyrapone in Patients With Hypercortisolism

Key facts

Who runs it
Istituto Auxologico Italiano
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
28 Apr 2022
Ended
31 Dec 2025
Type of study
Observational
Treatments tested
  • Metyrapone Capsules
Record updated
30 March 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients with mild Cushing's Syndrome not candidate for surgery
  • Current therapy with metyrapone since less than 1 week
  • Cortisol levels at 08:00 after 1 mg-overnight dexamethasone suppression test (1mgDST) >1.8 μg/dL
  • Confirmed with 2 mg two days dexamethasone suppression test (2mgx2dDST)
  • Presence of at least one out of the following conditions: type 2 diabetes mellitus, impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), arterial hypertension, bone mineral density (BMD) Z-score < -2.0 and/or fragility fracture at any skeletal site
  • Stable anti-hypertensive therapies and blood pressure (BP) levels in the month before enrolment
  • Stable anti-diabetic therapies and glycometabolic control during the month before enrolment
  • Stable body weight during the month before enrolment

Who cannot take part

  • Intake of drugs influencing cortisol metabolism and/or secretion
  • Malignant hypertension and/or BP <200/120 mmHg
  • Possible adrenal metastases or radiological features suggestive for adrenal malignancy (i.e. not homogeneous pattern, necrosis, calcifications, irregular margins, local invasion and high density at computed tomography)
  • Severe hyperglycemia (i.e. FG >350 mg/dL)
  • Women in child-bearing age
  • Signs and/or symptoms of overt hypercortisolism (striae rubrae, moon facies, easy bruising, buffalo hump, hypertrichosis)
  • Urinary free cortisol (UFC) higher than 1.5 fold the upper normal range
  • Presence of pheochromocytoma or primary hyperaldosteronism
  • Congenital adrenal hyperplasia
  • Patients with body mass index (BMI) >35 kg/m2

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.

The group in the trial

  • metyrapone treatment

    hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)

    Treatment: Metyrapone Capsules

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism
Record updated
30 March 2026